München
11.11.26 | 08:01
0,096 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 08.10. | Diamyd Medical AB Ser. B Q4 Loss Decreases | 1 | RTTNews | ||
| 07.10. | DIAMYD MEDICAL AB: Year-End Report 25/26 | 2 | Cision News | ||
| 07.10. | Diamyd Medical AB (publ): Year-End Report 25/26 | 248 | GlobeNewswire (Europe) | September 2025 - August 2026, Diamyd Medical AB (publ), Fiscal year 2025/2026
Financial summary (September 2025 - August 2026)
Net sales: MSEK 0.5 (0.1), fourth quarter: MSEK 0.1 (0.0)
Net result:... ► Artikel lesen | |
| 27.07. | Diamyd Medical AB (publ): Diamyd Medical Provides Update on Learnings from DIAGNODE-3 Interim Analysis | 322 | GlobeNewswire (Europe) | Review identifies potential contributing factors and informs future development considerations; no new safety concerns identified.
The pre-specified interim analysis included 174 of 321 enrolled participants... ► Artikel lesen | |
| 25.06. | Diamyd Medical AB (publ): Mathias Skalmstad new CFO at Diamyd Medical | 271 | GlobeNewswire (Europe) | Diamyd Medical is pleased to announce that Mathias Skalmstad will take up the position of Chief Financial Officer at Diamyd Medical as early as July 1st, 2026.
"With my extensive experience from both... ► Artikel lesen | |
| 24.06. | Diamyd Medical AB Ser. B Q3 Loss Climbs | 1 | RTTNews | ||
| 24.06. | Diamyd Medical AB (publ): Quarterly Report 3 25/26 | 431 | GlobeNewswire (Europe) | September 2025 - May 2026, Diamyd Medical AB (publ), Fiscal year 2025/2026
Diamyd Medical
Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes... ► Artikel lesen | |
| 23.06. | Diamyd Medical AB (publ): Diamyd Medical provides update on Strategic Review | 328 | GlobeNewswire (Europe) | Following the outcome of the DIAGNODE-3 study, the Company's immediate priority is to complete the close-out of the Phase 3 program in an efficient and responsible manner.
Upon completion of this process... ► Artikel lesen | |
| 18.06. | Diamyd Medical AB (publ): Diamyd Medical announces update regarding interim CFO | 236 | GlobeNewswire (Europe) | Diamyd Medical today announces that Anna Styrud, appointed interim CFO in Diamyd Medical, will not be able to start her position as previously communicated due to changes in her availability. A review... ► Artikel lesen | |
| 11.06. | Diamyd Medical AB (publ): Diamyd Medical receives Notice of Allowance for Key Precision Medicine Patent | 239 | GlobeNewswire (Europe) | Diamyd Medical has been given notice that the USPTO has allowed a patent application and is expected to proceed to grant a patent protecting the use of retogatein (GAD65) to treat individuals with type... ► Artikel lesen | |
| 05.06. | Diamyd Medical AB (publ): Diamyd Medical provides update on ongoing Activities | 243 | GlobeNewswire (Europe) | Diamyd Medical today announced that it, as part of an ongoing strategic review, has received several proposals from external parties, including formal non-binding Letters of Intent, as well as invitations... ► Artikel lesen | |
| 22.05. | Diamyd Medical AB (publ): Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company | 264 | GlobeNewswire (Europe) | A review to find a successor will now begin, and Niklas will remain with the company for some time to enable a handover to this person.
"Although Niklas has worked for Diamyd for a relatively short... ► Artikel lesen | |
| 20.05. | Diamyd Medical AB (publ): Diamyd Medical receives GMP certification and manufacturing authorization for biological investigational medicinal products for human use | 326 | GlobeNewswire (Europe) | Diamyd Medical today announced a significant advancement in the company's operations related to the manufacturing of biological medicines (biologics). The company has now received GMP (Good Manufacturing... ► Artikel lesen | |
| 11.05. | Diamyd Medical AB (publ): Diamyd Medical provides an update on strategic review and financial position | 489 | GlobeNewswire (Europe) | Diamyd Medical today announces that the initial phase of the strategic review, initiated following the discontinuation of the Phase 3 DIAGNODE-3 trial, has been completed.
Strategic review update
The... ► Artikel lesen | |
| 24.04. | Diamyd Medical AB (publ): Diamyd Medical announces governance and leadership update | 371 | GlobeNewswire (Europe) | Further to the Company's press release regarding governance changes following the March 27 interim analysis of its DIAGNODE-3 study, Diamyd Medical today announces that Chairman Anders Essen-Möller... ► Artikel lesen | |
| 23.04. | Diamyd Medical AB (publ): Diamyd Medical announces governance and leadership changes | 377 | GlobeNewswire (Europe) | Following Diamyd Medical's unexpectedly negative results from the March 27 interim analysis of its DIAGNODE-3 study, the Board of Directors has implemented governance changes to strengthen oversight... ► Artikel lesen | |
| 10.04. | Diamyd Medical AB (publ): Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming futility; initiates strategic review | 754 | GlobeNewswire (Europe) | Diamyd Medical today announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes. Following the previously reported interim analysis and... ► Artikel lesen | |
| 08.04. | Diamyd Medical AB (publ): Bulletin from Diamyd Medical's Extraordinary General Meeting 2026 | 511 | GlobeNewswire (Europe) | An Extraordinary general meeting of Diamyd Medical Aktiebolag (the "Company") was held on April 8, 2026.
The Extraordinary General Meeting resolved to approve the board of directors' resolution from... ► Artikel lesen | |
| 29.03. | Diamyd Medical AB (publ): Diamyd Medical updates on the interim efficacy analysis of Phase 3 DIAGNODE-3 trial | 618 | GlobeNewswire (Europe) | Diamyd Medical on Friday March 27th announced that the pre-specified interim efficacy analysis on 174 out of 321 participants of the ongoing Phase 3 DIAGNODE-3 trial yielded results that were unexpected... ► Artikel lesen | |
| 27.03. | Diamyd Medical AB: Diamyd Medical reports negative interim results of Phase 3 DIAGNODE-3 trial | 765 | GlobeNewswire (Europe) | Diamyd Medical today announced the completion of a pre-specified interim efficacy analysis on C-peptide in the ongoing pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 56,52 | -0,98 % | Bayer-Aktie mit +194% - droht jetzt ein Rückschlag? | Die Bayer-Aktie notiert nach einem Wochengewinn von mehr als +7% bei 54,24 €. Damit erreicht der Kurs eine wichtige Widerstandszone und testet zugleich den langfristigen Abwärtstrend. Während der RSI... ► Artikel lesen | |
| NOVO NORDISK | 36,250 | -0,63 % | Novo-Nordisk-Aktie: 3 Patentabläufe - droht jetzt die nächste Gewinnfalle? | Die Novo-Nordisk-Aktie hat nach den überraschend starken Quartalszahlen um rund +5,6% auf 285,20 Dänische Kronen zugelegt. Doch eine neue Entwicklung könnte den Turnaround erheblich erschweren. In gleich... ► Artikel lesen | |
| PFIZER | 26,305 | +0,06 % | Dividendenbekanntmachungen (06.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AG BARR PLC GB00B6XZKY75 0,0382 GBP EUR ALLIANCE RESOURCE PARTNERS LP US01877R1086 0,6 USD 0,5348 EUR AUBAY SA FR0000063737 - 0... ► Artikel lesen | |
| ABBVIE | 262,20 | -0,42 % | Eli Lilly kauft AtaiBeckley für 2,8 Milliarden Dollar - wer behandelt künftig die Patienten? | ||
| ROCHE | 434,84 | -0,68 % | Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems | Dedicated Cluj-Napoca team will advance LightCycler PRO and support Roche's established PCR platforms, keeping them secure, reliable and up to date Perficient, the global AI and technology consulting... ► Artikel lesen | |
| MERCK & CO | 131,86 | -0,57 % | Merck & Co. (MRK): US-Pharmagigant bereitet die nächste Rally vor! | Befreiungsschlag an der Widerstandslinie? Rückblick Im Chart sehen wir nach einer Seitwärtsphase einen steilen Anstieg bis August. Darauf folgte eine Konsolidierung. Die Bullen lauern nun knapp unterhalb... ► Artikel lesen | |
| ABBOTT LABORATORIES | 98,80 | -0,14 % | Abbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator lead | ||
| DERMAPHARM | 38,875 | +0,97 % | EQS-AFR: Dermapharm Holding SE: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: Dermapharm Holding SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Dermapharm Holding SE: Vorabbekanntmachung... ► Artikel lesen | |
| ZOETIS | 73,40 | -0,65 % | Zoetis Inc.: Zoetis to Participate in the Jefferies Global Healthcare Conference in London | Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference... ► Artikel lesen | |
| DOCMORRIS | 20,480 | +0,29 % | DEUTSCHE BANK RESEARCH stuft DocMorris auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für DocMorris nach der Ankündigung der Übernahme des Telemedizin-Anbieters Medi24 auf "Buy" mit einem Kursziel von 17,5 Franken... ► Artikel lesen | |
| PENTIXAPHARM | 1,840 | -1,34 % | Pentixapharm: Neue Impulse für die Aktie in Sicht | Pentixapharm könnte 2027 gleich mit zwei wichtigen Fortschritten aufwarten, die der zuletzt verhaltenen Kursentwicklung neue Impulse geben sollten. Zum einen soll die entscheidende klinische Studie... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 130,85 | +3,52 % | 405.262 US-Dollar pro Demenzfall - 70% tragen Familien: Warum Axsome, Lundbeck und NeuroThera beim Kostentreiber Agitation ansetzen | ||
| DAIICHI SANKYO | 15,898 | +0,16 % | Asking More of Science: How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care | ||
| TRULIEVE CANNABIS | 9,753 | -1,64 % | Trulieve Cannabis Corp.: Trulieve Reports Third Quarter 2026 Results | Third quarter revenue of $230 million, with 64% gross marginCash flow from operations of $183 million and free cash flow of $120 million* in first nine months of 2026Received final DEA registrations... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 16,250 | -0,73 % | RBC raises Acadia Pharmaceuticals stock price target on Daybue growth |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,096 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.